Common stock, par value $0.0001
- Symbol
- STLN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Starling Oncology, Inc.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-election to the Board of the Directors of the Company (the “Board”) at its 2027 annual meeting of stockholders (the “Annual Meeting”). Mr.…
Company context
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementAug 21, 2026
- 144 filingAug 21, 2026
- 10-Q filingAug 6, 2026
- Results of Operations and Financial ConditionAug 6, 2026
- Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureAug 3, 2026
Registered securities in this filing
STARLING ONCOLOGY, INC. · 8-K · Filed 2026-09-02
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share
- Symbol
- TOIIW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Historical · closed Aug 3, 2026
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
On September 1, 2026, Brad Hively
notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-election to the Board of the Directors
of the Company (the “Board”) at its 2027 annual meeting of stockholders (the “Annual Meeting”). Mr. Hively is
expected to continue to serve as a director of the Company until the Annual Meeting, but effective immediately, will no longer serve as
Vice Chairman of the Board or as a member of the Compliance Committee or any other committees of the Board. Mr. Hively’s decision
not to stand for re-election is not the result of any disagreement between the Company and him on any matter relating to Company’s
operations, policies or practices.